DSM Capital Partners’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-963
| Closed | -$134K | – | 66 |
|
|
2018
Q3 | $134K | Hold |
963
| – | – | ﹤0.01% | 51 |
|
|
2018
Q2 | $120K | Hold |
963
| – | – | ﹤0.01% | 50 |
|
|
2018
Q1 | $107K | Sell |
963
-757,246
| -100% | -$90.5M | ﹤0.01% | 48 |
|
|
2017
Q4 | $90.7M | Sell |
758,209
-651,941
| -46% | -$79.4M | 1.26% | 24 |
|
|
2017
Q3 | $198M | Buy |
1,410,150
+243,001
| +21% | +$33M | 2.8% | 15 |
|
|
2017
Q2 | $142M | Buy |
1,167,149
+153,233
| +15% | +$17.8M | 2.11% | 17 |
|
|
2017
Q1 | $123M | Sell |
1,013,916
-100,487
| -9% | -$13M | 2.01% | 21 |
|
|
2016
Q4 | $136M | Sell |
1,114,403
-51,224
| -4% | -$6.27M | 2.36% | 19 |
|
|
2016
Q3 | $143M | Sell |
1,165,627
-144,802
| -11% | -$18.6M | 2.3% | 19 |
|
|
2016
Q2 | $153M | Sell |
1,310,429
-53,154
| -4% | -$7.54M | 2.63% | 20 |
|
|
2016
Q1 | $190M | Sell |
1,363,583
-8,592
| -0.6% | -$1.26M | 3.11% | 14 |
|
|
2015
Q4 | $262M | Buy |
1,372,175
+124,788
| +10% | +$21.8M | 4.1% | 8 |
|
|
2015
Q3 | $195M | Sell |
1,247,387
-11,315
| -0.9% | -$2.06M | 3.63% | 9 |
|
|
2015
Q2 | $228M | Buy |
1,258,702
+322,305
| +34% | +$55.6M | 3.88% | 7 |
|
|
2015
Q1 | $162M | Sell |
936,397
-651,419
| -41% | -$118M | 2.78% | 16 |
|
|
2014
Q4 | $294M | Sell |
1,587,816
-10,220
| -0.6% | -$1.89M | 5.42% | 4 |
|
|
2014
Q3 | $265M | Buy |
1,598,036
+7,007
| +0.4% | +$1.15M | 5.26% | 2 |
|
|
2014
Q2 | $249M | Buy |
1,591,029
+563,868
| +55% | +$89M | 5.05% | 4 |
|
|
2014
Q1 | $156M | Sell |
1,027,161
-284,827
| -22% | -$45.3M | 3.26% | 13 |
|
|
2013
Q4 | $174M | Buy |
1,311,988
+257,523
| +24% | +$30.9M | 3.49% | 13 |
|
|
2013
Q3 | $122M | Sell |
1,054,465
-266,712
| -20% | -$29.3M | 2.77% | 19 |
|
|
2013
Q2 | $122M | Buy |
+1,321,177
| New | +$127M | 3.03% | 20 |
|
Other funds holding ALXN
BBA
